Although our analyses of tumor responses and overall survival are based on very small numbers and late-stage cancer patients, alternative combination regimens disrupting the metabolism in IDH1/2-mutated cancers should be investigated in future studies. This evidence concerns the gene IDH1 and neoplasm.